Parabilis filed for an initial public offering a day after signing a strategic research collaboration with Regeneron worth up to $2.3 billion. The agreement covers antibody-Helicon conjugates and includes a concurrent private placement in which Regeneron will purchase about $75 million of Parabilis shares at 90% of the IPO price per share.